Contact
searchSearch
HMP Global
Login

October 2021

Editor's Page
Early Impressions From OCPC 2021
10/20/2021
Winston Wong, PharmD
Winston Wong, PharmD, Editor-in-Chief, discusses the features in this issue, which cover new technology that may help guide treatment decisions for patients with metastatic breast cancer and differences in referral patterns and treatment...
Winston Wong, PharmD, Editor-in-Chief, discusses the features in this issue, which cover new technology that may help guide treatment decisions for patients with metastatic breast cancer and differences in referral patterns and treatment...
Winston Wong, PharmD,...
10/20/2021
Journal of Clinical Pathways
Letters to the Editor
Atezolizumab Plus Bevacizumab Is Cost-Effective for Advanced HCC When Utilizing Biosimilars
10/20/2021
Aimee Ginsburg, PharmD, BCPS; Kaci Dominguez, PharmD; Leslie T. Busby, MD; Josh Howell, PharmD, BCOP
Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.
Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.
Aimee Ginsburg, PharmD, BCPS,...
10/20/2021
Journal of Clinical Pathways
Clinical Pathways GPS
Medicare Drug Benefit ... The ABCDs
10/20/2021
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the drug benefits provided under each of the current Medicare Parts and the future of Medicare design.
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the drug benefits provided under each of the current Medicare Parts and the future of Medicare design.
Richard G. Stefanacci, DO, MGH,...
10/20/2021
Journal of Clinical Pathways
Trending From ACCC
Measurable Residual Disease Testing Implementation Roadmap for Patients With ALL
10/20/2021
The Association of Community Cancer Centers developed an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain MRD testing for adult patients with ALL.
The Association of Community Cancer Centers developed an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain MRD testing for adult patients with ALL.
The Association of Community...
10/20/2021
Journal of Clinical Pathways
Pharma Insights
COVID-19 and Diabetes: Strategies to Catch Up
10/20/2021
Cynthia Miller, MD, MPH, FACP
Cynthia Miller, MD, MPH, FACP, discusses initiatives pharmaceutical companies can employ to assist physician groups and payers in adding appropriate pharmacologic therapies to reduce the burden of COVID-19 on persons with diabetes.
Cynthia Miller, MD, MPH, FACP, discusses initiatives pharmaceutical companies can employ to assist physician groups and payers in adding appropriate pharmacologic therapies to reduce the burden of COVID-19 on persons with diabetes.
Cynthia Miller, MD, MPH, FACP,...
10/20/2021
Journal of Clinical Pathways
Research Reports
Potential Cost Effectiveness of FES-PET to Determine Estrogen Receptor Status in Metastatic Breast Cancer in the United States
10/20/2021
Hannah M. Linden, MD; Poorni M. Manohar, MD; Josh A. Roth, PhD, MHA
Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.
Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.
Poorni M. Manohar, MD, et al...
10/20/2021
Journal of Clinical Pathways
From the Field
Referral Patterns and Treatment Preferences in Patients With Advanced Prostate Cancer: Differences Between Medical Oncologists and Urologists
10/20/2021
Skyler Hime Rupard, MS; Ajeet Gajra, MD, FACP; Yolaine J. Jeune-Smith, PhD; Bruce A. Feinberg, DO
Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer
Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer
Ajeet Gajra, MD, FACP, et al...
10/20/2021
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

October 2021 Volume 7 Issue 8

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use